Polish Myeloma Consortium
4 clinical trials · Sponsor
◉ Watch Polish Myeloma Consortium
| Record | Firm | Date |
|---|---|---|
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. (NCT07748689) | Polish Myeloma Consortium | 2026-10-01 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease (NCT07740486) | Polish Myeloma Consortium | 2026-09-01 |
| Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (NCT03697655) | Polish Myeloma Consortium | 2018-12-10 |
| A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 (NCT03679455) | Polish Myeloma Consortium | 2018-09-21 |
Track Polish Myeloma Consortium automatically
Every clearance here is in the API, with alerts when new ones post.